BridgeBio Pharma (BBIO) Enterprise Value (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Enterprise Value for 7 consecutive years, with -$576.9 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 65.0% to -$576.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$576.9 million through Dec 2025, down 65.0% year-over-year, with the annual reading at -$576.9 million for FY2025, 65.0% down from the prior year.
- Enterprise Value hit -$576.9 million in Q4 2025 for BridgeBio Pharma, down from -$276.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$276.0 million in Q3 2025 to a low of -$917.8 million in Q1 2021.
- Historically, Enterprise Value has averaged -$529.1 million across 5 years, with a median of -$508.5 million in 2023.
- Biggest five-year swings in Enterprise Value: tumbled 28985.87% in 2021 and later soared 49.62% in 2023.
- Year by year, Enterprise Value stood at -$390.5 million in 2021, then fell by 3.28% to -$403.3 million in 2022, then fell by 5.03% to -$423.6 million in 2023, then increased by 17.47% to -$349.6 million in 2024, then plummeted by 65.0% to -$576.9 million in 2025.
- Business Quant data shows Enterprise Value for BBIO at -$576.9 million in Q4 2025, -$276.0 million in Q3 2025, and -$747.0 million in Q2 2025.